Key result
Personalized antithrombotic strategies in cardiogenic shock require repeated monitoring to balance prothrombotic and bleeding risks.
Why the study?
In cardiogenic shock, the coexistence of a prothrombotic state and high bleeding risk complicates the selection of an optimal antithrombotic strategy.
This review provides an overview of current evidence and practical guidance for personalized antithrombotic strategies in patients with cardiogenic shock, balancing prothrombotic and bleeding risks.
Supports repeated risk assessment for antithrombotic therapy in cardiogenic shock; leaves open prospective validation of personalized protocols.
Cardiogenic shock (CS) represents a critical condition with a high mortality rate. The most common cause of CS is coronary artery disease, and patients typically present with myocardial infarction, necessitating immediate treatment through percutaneous coronary intervention (PCI) and often requiring mechanical circulatory support. CS is associated with a prothrombotic situation, while on the other hand, there is often a significant risk of bleeding. This dual challenge complicates the selection of an optimal antithrombotic strategy. The choice of antithrombotic agents must be personalized, taking into consideration all relevant conditions. Repeated risk assessment, therapeutic monitoring, and adjusting antithrombotic therapy are mandatory in these patients. This review article aims to provide an overview of the current evidence and practical guidance on antithrombotic strategies in the context of CS.
No takes yet. Share an insight, caveat, or question.
Droppa et al. (2024) conducted a review in Cardiogenic shock. Antithrombotic strategies was evaluated. Personalized antithrombotic strategies in cardiogenic shock require repeated risk assessment and therapeutic monitoring to balance prothrombotic and bleeding risks.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: